Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 373


Multiple drug resistance in the canine hookworm Ancylostoma caninum: an emerging threat?

Jimenez Castro PD, Howell SB, Schaefer JJ, Avramenko RW, Gilleard JS, Kaplan RM.

Parasit Vectors. 2019 Dec 9;12(1):576. doi: 10.1186/s13071-019-3828-6.


Securing the Payload, Finding the Cell, and Avoiding the Endosome: Peptide-Targeted, Fusogenic Porous Silicon Nanoparticles for Delivery of siRNA.

Kim B, Sun S, Varner JA, Howell SB, Ruoslahti E, Sailor MJ.

Adv Mater. 2019 Aug;31(35):e1902952. doi: 10.1002/adma.201902952. Epub 2019 Jul 3.


Tumor-Targeting, MicroRNA-Silencing Porous Silicon Nanoparticles for Ovarian Cancer Therapy.

Bertucci A, Kim KH, Kang J, Zuidema JM, Lee SH, Kwon EJ, Kim D, Howell SB, Ricci F, Ruoslahti E, Jang HJ, Sailor MJ.

ACS Appl Mater Interfaces. 2019 Jul 10;11(27):23926-23937. doi: 10.1021/acsami.9b07980. Epub 2019 Jun 28.


Refugia and anthelmintic resistance: Concepts and challenges.

Hodgkinson JE, Kaplan RM, Kenyon F, Morgan ER, Park AW, Paterson S, Babayan SA, Beesley NJ, Britton C, Chaudhry U, Doyle SR, Ezenwa VO, Fenton A, Howell SB, Laing R, Mable BK, Matthews L, McIntyre J, Milne CE, Morrison TA, Prentice JC, Sargison ND, Williams DJL, Wolstenholme AJ, Devaney E.

Int J Parasitol Drugs Drug Resist. 2019 Aug;10:51-57. doi: 10.1016/j.ijpddr.2019.05.001. Epub 2019 May 17. Review.


Tumor Retention of Enzyme-Responsive Pt(II) Drug-Loaded Nanoparticles Imaged by Nanoscale Secondary Ion Mass Spectrometry and Fluorescence Microscopy.

Proetto MT, Callmann CE, Cliff J, Szymanski CJ, Hu D, Howell SB, Evans JE, Orr G, Gianneschi NC.

ACS Cent Sci. 2018 Nov 28;4(11):1477-1484. doi: 10.1021/acscentsci.8b00444. Epub 2018 Oct 23.


APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells.

Local A, Zhang H, Benbatoul KD, Folger P, Sheng X, Tsai CY, Howell SB, Rice WG.

Mol Cancer Ther. 2018 Jun;17(6):1177-1186. doi: 10.1158/1535-7163.MCT-17-1209. Epub 2018 Apr 6.


APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency.

Tsai CY, Sun S, Zhang H, Local A, Su Y, Gross LA, Rice WG, Howell SB.

Mol Cancer Ther. 2018 Jun;17(6):1167-1176. doi: 10.1158/1535-7163.MCT-17-0834. Epub 2018 Apr 6.


LGR5 and LGR6 in stem cell biology and ovarian cancer.

Schindler AJ, Watanabe A, Howell SB.

Oncotarget. 2017 Aug 11;9(1):1346-1355. doi: 10.18632/oncotarget.20178. eCollection 2018 Jan 2. Review.


Motility in the L3 stage is a poor phenotype for detecting and measuring resistance to avermectin/milbemycin drugs in gastrointestinal nematodes of livestock.

George MM, Lopez-Soberal L, Storey BE, Howell SB, Kaplan RM.

Int J Parasitol Drugs Drug Resist. 2018 Apr;8(1):22-30. doi: 10.1016/j.ijpddr.2017.12.002. Epub 2017 Dec 18.


Multi-drug resistant Haemonchus contortus in a sheep flock in Antioquia, Colombia.

Chaparro JJ, Villar D, Zapata JD, López S, Howell SB, López A, Storey BE.

Vet Parasitol Reg Stud Reports. 2017 Dec;10:29-34. doi: 10.1016/j.vprsr.2017.07.005. Epub 2017 Jul 18.


Validation of the FAMACHA© system in South American camelids.

Storey BE, Williamson LH, Howell SB, Terrill TH, Berghaus R, Vidyashankar AN, Kaplan RM.

Vet Parasitol. 2017 Aug 30;243:85-91. doi: 10.1016/j.vetpar.2017.06.004. Epub 2017 Jun 26.


Utilization of composite fecal samples for detection of anthelmintic resistance in gastrointestinal nematodes of cattle.

George MM, Paras KL, Howell SB, Kaplan RM.

Vet Parasitol. 2017 Jun 15;240:24-29. doi: 10.1016/j.vetpar.2017.04.024. Epub 2017 Apr 27.


A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Jandial DA, Brady WE, Howell SB, Lankes HA, Schilder RJ, Beumer JH, Christner SM, Strychor S, Powell MA, Hagemann AR, Moore KN, Walker JL, DiSilvestro PA, Duska LR, Fracasso PM, Dizon DS.

Gynecol Oncol. 2017 May;145(2):236-242. doi: 10.1016/j.ygyno.2017.03.013. Epub 2017 Mar 22.


Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity.

Bompiani KM, Tsai CY, Achatz FP, Liebig JK, Howell SB.

Metallomics. 2016 Sep 1;8(9):951-62. doi: 10.1039/c6mt00076b. Epub 2016 May 9.


Cellular Delivery of Nanoparticles Revealed with Combined Optical and Isotopic Nanoscopy.

Proetto MT, Anderton CR, Hu D, Szymanski CJ, Zhu Z, Patterson JP, Kammeyer JK, Nilewski LG, Rush AM, Bell NC, Evans JE, Orr G, Howell SB, Gianneschi NC.

ACS Nano. 2016 Apr 26;10(4):4046-54. doi: 10.1021/acsnano.5b06477. Epub 2016 Mar 29.


Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery.

Muggia FM, Bonetti A, Hoeschele JD, Rozencweig M, Howell SB.

J Clin Oncol. 2015 Dec 10;33(35):4219-26. doi: 10.1200/JCO.2015.60.7481. Epub 2015 Oct 26. No abstract available.


The copper transporter 1 (CTR1) is required to maintain the stability of copper transporter 2 (CTR2).

Tsai CY, Liebig JK, Tsigelny IF, Howell SB.

Metallomics. 2015 Nov;7(11):1477-87. doi: 10.1039/c5mt00131e. Epub 2015 Jul 24.


Cisplatin inhibits MEK1/2.

Yamamoto T, Tsigelny IF, Götz AW, Howell SB.

Oncotarget. 2015 Sep 15;6(27):23510-22.


A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.

Sugahara KN, Scodeller P, Braun GB, de Mendoza TH, Yamazaki CM, Kluger MD, Kitayama J, Alvarez E, Howell SB, Teesalu T, Ruoslahti E, Lowy AM.

J Control Release. 2015 Aug 28;212:59-69. doi: 10.1016/j.jconrel.2015.06.009. Epub 2015 Jun 11.


Integrin αV control of Cu homeostasis and cisplatin sensitivity.

Lin X, Shang X, Howell SB.

Cell Cycle. 2014;13(21):3317-8. doi: 10.4161/15384101.2014.973746. No abstract available.


Claudin-4 controls the receptor tyrosine kinase EphA2 pro-oncogenic switch through β-catenin.

Shang X, Lin X, Howell SB.

Cell Commun Signal. 2014 Oct 25;12:59. doi: 10.1186/s12964-014-0059-5.


Reactive oxygen species promote ovarian cancer progression via the HIF-1α/LOX/E-cadherin pathway.

Wang Y, Ma J, Shen H, Wang C, Sun Y, Howell SB, Lin X.

Oncol Rep. 2014 Nov;32(5):2150-8. doi: 10.3892/or.2014.3448. Epub 2014 Aug 28.


Antiparasitic efficacy of a novel plant-based functional food using an Ascaris suum model in pigs.

Kaplan RM, Storey BE, Vidyashankar AN, Bissinger BW, Mitchell SM, Howell SB, Mason ME, Lee MD, Pedroso AA, Akashe A, Skrypec DJ.

Acta Trop. 2014 Nov;139:15-22. doi: 10.1016/j.actatropica.2014.06.008. Epub 2014 Jun 27.


Molecular modulation of the copper and cisplatin transport function of CTR1 and its interaction with IRS-4.

Tsai CY, Larson CA, Safaei R, Howell SB.

Biochem Pharmacol. 2014 Aug 15;90(4):379-87. doi: 10.1016/j.bcp.2014.06.019. Epub 2014 Jun 23.


An Earth-sized planet in the habitable zone of a cool star.

Quintana EV, Barclay T, Raymond SN, Rowe JF, Bolmont E, Caldwell DA, Howell SB, Kane SR, Huber D, Crepp JR, Lissauer JJ, Ciardi DR, Coughlin JL, Everett ME, Henze CE, Horch E, Isaacson H, Ford EB, Adams FC, Still M, Hunter RC, Quarles B, Selsis F.

Science. 2014 Apr 18;344(6181):277-80. doi: 10.1126/science.1249403.


Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin.

Huang CP, Fofana M, Chan J, Chang CJ, Howell SB.

Metallomics. 2014 Mar;6(3):654-61. doi: 10.1039/c3mt00331k. Epub 2014 Feb 13.


Cisplatin induces resistance by triggering differentiation of testicular embryonal carcinoma cells.

Abada PB, Howell SB.

PLoS One. 2014 Jan 27;9(1):e87444. doi: 10.1371/journal.pone.0087444. eCollection 2014.


Characterization of a monoclonal antibody capable of reliably quantifying expression of human Copper Transporter 1 (hCTR1).

Quail JF, Tsai CY, Howell SB.

J Trace Elem Med Biol. 2014 Apr;28(2):151-159. doi: 10.1016/j.jtemb.2013.12.003. Epub 2013 Dec 18.


Dynamics of soft nanomaterials captured by transmission electron microscopy in liquid water.

Proetto MT, Rush AM, Chien MP, Abellan Baeza P, Patterson JP, Thompson MP, Olson NH, Moore CE, Rheingold AL, Andolina C, Millstone J, Howell SB, Browning ND, Evans JE, Gianneschi NC.

J Am Chem Soc. 2014 Jan 29;136(4):1162-5. doi: 10.1021/ja408513m. Epub 2014 Jan 14.


In vivo time-gated fluorescence imaging with biodegradable luminescent porous silicon nanoparticles.

Gu L, Hall DJ, Qin Z, Anglin E, Joo J, Mooney DJ, Howell SB, Sailor MJ.

Nat Commun. 2013;4:2326. doi: 10.1038/ncomms3326.


Regulation of the Epithelial-Mesenchymal Transition by Claudin-3 and Claudin-4.

Lin X, Shang X, Manorek G, Howell SB.

PLoS One. 2013 Jun 21;8(6):e67496. doi: 10.1371/journal.pone.0067496. Print 2013.


The same frequency of planets inside and outside open clusters of stars.

Meibom S, Torres G, Fressin F, Latham DW, Rowe JF, Ciardi DR, Bryson ST, Rogers LA, Henze CE, Janes K, Barnes SA, Marcy GW, Isaacson H, Fischer DA, Howell SB, Horch EP, Jenkins JM, Schuler SC, Crepp J.

Nature. 2013 Jul 4;499(7456):55-8. doi: 10.1038/nature12279. Epub 2013 Jun 26.


The role of metal binding and phosphorylation domains in the regulation of cisplatin-induced trafficking of ATP7B.

Safaei R, Adams PL, Mathews RA, Manorek G, Howell SB.

Metallomics. 2013 Aug;5(8):964-72. doi: 10.1039/c3mt00131h.


Kepler-62: a five-planet system with planets of 1.4 and 1.6 Earth radii in the habitable zone.

Borucki WJ, Agol E, Fressin F, Kaltenegger L, Rowe J, Isaacson H, Fischer D, Batalha N, Lissauer JJ, Marcy GW, Fabrycky D, Désert JM, Bryson ST, Barclay T, Bastien F, Boss A, Brugamyer E, Buchhave LA, Burke C, Caldwell DA, Carter J, Charbonneau D, Crepp JR, Christensen-Dalsgaard J, Christiansen JL, Ciardi D, Cochran WD, DeVore E, Doyle L, Dupree AK, Endl M, Everett ME, Ford EB, Fortney J, Gautier TN 3rd, Geary JC, Gould A, Haas M, Henze C, Howard AW, Howell SB, Huber D, Jenkins JM, Kjeldsen H, Kolbl R, Kolodziejczak J, Latham DW, Lee BL, Lopez E, Mullally F, Orosz JA, Prsa A, Quintana EV, Sanchis-Ojeda R, Sasselov D, Seader S, Shporer A, Steffen JH, Still M, Tenenbaum P, Thompson SE, Torres G, Twicken JD, Welsh WF, Winn JN.

Science. 2013 May 3;340(6132):587-90. doi: 10.1126/science.1234702. Epub 2013 Apr 18.


A sub-Mercury-sized exoplanet.

Barclay T, Rowe JF, Lissauer JJ, Huber D, Fressin F, Howell SB, Bryson ST, Chaplin WJ, Désert JM, Lopez ED, Marcy GW, Mullally F, Ragozzine D, Torres G, Adams ER, Agol E, Barrado D, Basu S, Bedding TR, Buchhave LA, Charbonneau D, Christiansen JL, Christensen-Dalsgaard J, Ciardi D, Cochran WD, Dupree AK, Elsworth Y, Everett M, Fischer DA, Ford EB, Fortney JJ, Geary JC, Haas MR, Handberg R, Hekker S, Henze CE, Horch E, Howard AW, Hunter RC, Isaacson H, Jenkins JM, Karoff C, Kawaler SD, Kjeldsen H, Klaus TC, Latham DW, Li J, Lillo-Box J, Lund MN, Lundkvist M, Metcalfe TS, Miglio A, Morris RL, Quintana EV, Stello D, Smith JC, Still M, Thompson SE.

Nature. 2013 Feb 28;494(7438):452-4. doi: 10.1038/nature11914. Epub 2013 Feb 20. Erratum in: Nature. 2013 Apr 11;496(7444):252.


Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases.

Shang X, Lin X, Alvarez E, Manorek G, Howell SB.

Neoplasia. 2012 Oct;14(10):974-85.


Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.

Shang X, Lin X, Manorek G, Howell SB.

Mol Pharmacol. 2013 Jan;83(1):85-94. doi: 10.1124/mol.112.079798. Epub 2012 Oct 10.


Copper influx transporter 1 is required for FGF, PDGF and EGF-induced MAPK signaling.

Tsai CY, Finley JC, Ali SS, Patel HH, Howell SB.

Biochem Pharmacol. 2012 Oct 15;84(8):1007-13. doi: 10.1016/j.bcp.2012.07.014. Epub 2012 Jul 25.


Sec61β controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A.

Abada PB, Larson CA, Manorek G, Adams P, Howell SB.

Mol Pharmacol. 2012 Sep;82(3):510-20. doi: 10.1124/mol.112.079822. Epub 2012 Jun 18.


An all-atom model of the structure of human copper transporter 1.

Tsigelny IF, Sharikov Y, Greenberg JP, Miller MA, Kouznetsova VL, Larson CA, Howell SB.

Cell Biochem Biophys. 2012 Jul;63(3):223-34. doi: 10.1007/s12013-012-9358-x.


The CXXC motifs in the metal binding domains are required for ATP7B to mediate resistance to cisplatin.

Safaei R, Adams PL, Maktabi MH, Mathews RA, Howell SB.

J Inorg Biochem. 2012 May;110:8-17. doi: 10.1016/j.jinorgbio.2012.02.016. Epub 2012 Mar 3.


A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Gold MA, Brady WE, Lankes HA, Rose PG, Kelley JL, De Geest K, Crispens MA, Resnick KE, Howell SB.

Gynecol Oncol. 2012 Jun;125(3):635-9. doi: 10.1016/j.ygyno.2012.03.023. Epub 2012 Mar 22.


Transiting circumbinary planets Kepler-34 b and Kepler-35 b.

Welsh WF, Orosz JA, Carter JA, Fabrycky DC, Ford EB, Lissauer JJ, Prša A, Quinn SN, Ragozzine D, Short DR, Torres G, Winn JN, Doyle LR, Barclay T, Batalha N, Bloemen S, Brugamyer E, Buchhave LA, Caldwell C, Caldwell DA, Christiansen JL, Ciardi DR, Cochran WD, Endl M, Fortney JJ, Gautier TN 3rd, Gilliland RL, Haas MR, Hall JR, Holman MJ, Howard AW, Howell SB, Isaacson H, Jenkins JM, Klaus TC, Latham DW, Li J, Marcy GW, Mazeh T, Quintana EV, Robertson P, Shporer A, Steffen JH, Windmiller G, Koch DG, Borucki WJ.

Nature. 2012 Jan 11;481(7382):475-9. doi: 10.1038/nature10768.


Two Earth-sized planets orbiting Kepler-20.

Fressin F, Torres G, Rowe JF, Charbonneau D, Rogers LA, Ballard S, Batalha NM, Borucki WJ, Bryson ST, Buchhave LA, Ciardi DR, Désert JM, Dressing CD, Fabrycky DC, Ford EB, Gautier TN 3rd, Henze CE, Holman MJ, Howard A, Howell SB, Jenkins JM, Koch DG, Latham DW, Lissauer JJ, Marcy GW, Quinn SN, Ragozzine D, Sasselov DD, Seager S, Barclay T, Mullally F, Seader SE, Still M, Twicken JD, Thompson SE, Uddin K.

Nature. 2011 Dec 20;482(7384):195-8. doi: 10.1038/nature10780.


Aggregation properties of a polymeric anticancer therapeutic: a coarse-grained modeling study.

Peng LX, Yu L, Howell SB, Gough DA.

J Chem Inf Model. 2011 Dec 27;51(12):3030-5. doi: 10.1021/ci200214m. Epub 2011 Nov 21.


Effects of solution concentration on the physicochemical properties of a polymeric anticancer therapeutic.

Peng LX, Yu L, Howell SB, Gough DA.

Mol Pharm. 2012 Jan 1;9(1):37-47. doi: 10.1021/mp2002208. Epub 2011 Nov 22.


Kepler-16: a transiting circumbinary planet.

Doyle LR, Carter JA, Fabrycky DC, Slawson RW, Howell SB, Winn JN, Orosz JA, Prša A, Welsh WF, Quinn SN, Latham D, Torres G, Buchhave LA, Marcy GW, Fortney JJ, Shporer A, Ford EB, Lissauer JJ, Ragozzine D, Rucker M, Batalha N, Jenkins JM, Borucki WJ, Koch D, Middour CK, Hall JR, McCauliff S, Fanelli MN, Quintana EV, Holman MJ, Caldwell DA, Still M, Stefanik RP, Brown WR, Esquerdo GA, Tang S, Furesz G, Geary JC, Berlind P, Calkins ML, Short DR, Steffen JH, Sasselov D, Dunham EW, Cochran WD, Boss A, Haas MR, Buzasi D, Fischer D.

Science. 2011 Sep 16;333(6049):1602-6. doi: 10.1126/science.1210923.


A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells.

Piotrowicz RS, Damaj BB, Hachicha M, Incardona F, Howell SB, Finlayson M.

Mol Cancer Ther. 2011 Nov;10(11):2072-82. doi: 10.1158/1535-7163.MCT-11-0351. Epub 2011 Sep 1.


Cisplatin-loaded porous Si microparticles capped by electroless deposition of platinum.

Park JS, Kinsella JM, Jandial DD, Howell SB, Sailor MJ.

Small. 2011 Jul 18;7(14):2061-9. doi: 10.1002/smll.201100438. Epub 2011 Jun 1.


Porous silicon nanoparticle photosensitizers for singlet oxygen and their phototoxicity against cancer cells.

Xiao L, Gu L, Howell SB, Sailor MJ.

ACS Nano. 2011 May 24;5(5):3651-9. doi: 10.1021/nn1035262. Epub 2011 Apr 6.

Supplemental Content

Loading ...
Support Center